Human Papillomavirus and Cervical Cancer (2024)

1. ACOG – American College of Gynecologists and Obstetricians. Practice Bulletin No. 140: Management of abnormal cervical cancer screening test results and cervical cancer precursors. Obstet Gynecol2013; 122: 1338–67. [PubMed] [Google Scholar]

2. ACOG – American College of Obstetricians and Gynecologists. Committee Opinion No. 704: Human papillomavirus vaccination. Obstet Gynecol2017; 129: e173–8 [PubMed] [Google Scholar]

3. Adam E, Berkova Z, Daxnerova Z, Icenogle J, Reeves WC, Kaufman RH. Papillomavirus detection: demographic and behavioral characteristics influencing the identification of cervical disease. Am. J. Obstet. Gynecol2000; 182:257–264. [PubMed] [Google Scholar]

4. Agida T, Akaba G, Isah A, Ekele B. Knowledge and perception of human papilloma virus vaccine among the antenatal women in a Nigerian tertiary hospital. Niger Med J. 2015; 56(1): 23–27. [PMC free article] [PubMed] [Google Scholar]

5. Andersson S, Rylander E, Larsson B, Strand A, Silfversvard C, Wilander E. The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur. J. Cancer2001; 37:246–250. [PubMed] [Google Scholar]

6. Appleby P, Beral V, Berrington de Gonzáles A, Colin D, Franceschi S, Green J, et al. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer2006; 119: 1108–1124. [PubMed] [Google Scholar]

7. Apt D, Watts RM, Suske G, Bernard U. High Sp1/Sp3 ratios in epithelial cells during epithelial differentiation and cellular transcription correlate with the activation of the HPV-16 promoter. Virology1996; 224: 281–291. [PubMed] [Google Scholar]

8. Autier P, Coibion M, Huet F, Grivegnee AR. Transformation zone location and intraepithelial neoplasia of the cervix uteri. Br J Cancer1996; 74: 488–490. [PMC free article] [PubMed] [Google Scholar]

9. Baker TS, Newcomb WW, Olson NH, Cowsert LM, Olson C, Brown JC. Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys. J1991; 60:1445–1456. [PMC free article] [PubMed] [Google Scholar]

10. Bao YP, Li N, Smith JS, Qiao YL; ACCPAB members: human papillomavirus type distribution in women from Asia: a meta-analysis. Int J Gynecol Cancer. 2008;18(1):71–9. [PubMed] [Google Scholar]

11. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers. in 185 Countries. CA Cancer J Clin2018; 68(6): 394–424 [PubMed] [Google Scholar]

12. Brisson J, Morin K, Fortier M, Roy M, Bouchard C, Leclerc J, et al. Risk factors for cervical intraepithelial neoplasia: differences between low and high-grade lesions. Am. J. Epidemiol. 1994; 40:700–710. [PubMed] [Google Scholar]

14. Burk RD, Kelly P, Feldman J, Bromberg J, Vermund SH, Deltovitz JA, et al. Declining presence of cervicovagin*l human papilllomavirus infection with age is independent of other risk factors. Sex. Transm. Dis. 1996; 23: 333–341. [PubMed] [Google Scholar]

15. Calore EE, Pereira SMM, Cavaliere MJ. Progression of cervical lesions in HIV-seropositive women: a cytological study. Diagn. Cytopathol2001; 24: 117–119. [PubMed] [Google Scholar]

16. Capra G, Giovannelli L, Matranga D, Bellavia C, Guarneri MF, Fasciana T, et al. Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in Sicily. Hum Vaccin Immunother. 2017; 13(8): 1839–1843. [PMC free article] [PubMed] [Google Scholar]

17. Cárdenas-Turanzas M, Nogueras-Gonzalez GM, Scheurer ME, Adler-Storthz K, Benedet JL, Beck JR, et al. The Performance of Human Papillomavirus High-Risk DNA Testing in the Screening and Diagnostic SettingsCancer Epidemiol Biomarkers Prev. 2008; 17(10): 2865–2871. [PMC free article] [PubMed] [Google Scholar]

18. Castle PE. Beyond human papillomavirus: the cervix, exogenous secondary factors, and the development of cervical precancer and cancer. J Low Genit Tract Dis. 2004; 8: 224–230. [PubMed] [Google Scholar]

19. Catarino R, Petignat P, Dongui G, Vassilakos P. Cervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choices. World J Clin Oncol. 2015; 6(6): 281–290. [PMC free article] [PubMed] [Google Scholar]

20. Chua KL, Hjerpe A. Persistence of human papillomavirus (HPV) infections preceding cervical carcinoma. Cancer1996; 77: 121–127. [PubMed] [Google Scholar]

21. Conely LK, Ellerbrock TV, Bush TJ, Chiasson MA, Sawo D, Wright TC. HIV-1 infection and risk of vulvovagin*l and perianal condylomata acuminate and intraepithelial neoplasia; a prospective cohort study. Lancet2002; 359(9301): 108–113. [PubMed] [Google Scholar]

22. Cubie HA, Seagar AL, Beattie GJ, Monaghan S, Williams ARW. A longitudinal study if HPV detection and cervical pathology in HIV infected women. Sex. Transm. Infect. 2000; 76:257–261. [PMC free article] [PubMed] [Google Scholar]

23. de Araujo Souza PS, Villa LL. Genetic susceptibility to infection with human papillomavirus and development of cervical cancer in women in Brazil. Mutat Res. 2003; 544(2-3): 375–83. [PubMed] [Google Scholar]

24. Denny LCervical Cancer: Prevention and Treatment. Discov Med. 2012; 14(75):125–131 [PubMed] [Google Scholar]

25. de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX. Worldwide Prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2003; 7(7): 453–9. [PubMed] [Google Scholar]

26. Erickson BK, Alvarez RD, Huh WK. Human papillomavirus: What every provider should know. Am. J. Obstet. Gynecol. 2013; 208(3): 169–175. [PMC free article] [PubMed] [Google Scholar]

27. Ezenwa BN, Balogun MR, Okafor IP. Mothers’ human papilloma virus knowledge and willingness to vaccinate their adolescent daughters in Lagos, Nigeria. Int J Womens Health. 2013; 5: 371–377. [PMC free article] [PubMed] [Google Scholar]

28. Favre MStructural polypeptides of rabbit, bovine, and human papillomaviruses. J. Virol. 1975; 15: 1239–1247. [PMC free article] [PubMed] [Google Scholar]

29. Franco EL. Cancer causes revisited: human papillomavirus and cervical neoplasia. J. Natl. Cancer Inst. 1995; 87: 779–780. [PubMed] [Google Scholar]

30. Gichangi P, Estambale B, Bwayo J, Rogo K, Ojwang S, Opiyo Aet al. Knowledge and practice about cervical cancer and Pap smear testing among patients at Kenyatta National Hospital, Nairobi, Kenya. Int J Gynecol Cancer. 2003; 13(6): 827–833. [PubMed] [Google Scholar]

31. Giorgi C, Franconi R, Rybicki EP. Human papillomavirus vaccines in plants. Expert. Rev. Vaccin. 2010; 9(8): 913–924. [PubMed] [Google Scholar]

32. GLOBOCAN 2012 database. Cervical Cancer: Estimated Incidence, Mortality and Prevalence Worldwide in 2012. International Agency for Research on Cancer; Accessed July 15, 2018. [Google Scholar]

33. Harris TG, Burk RD, Palesky JM, Massad S, Bang JY, Anastos K,et al. Incidence of Cervical Squamous Intraepithelial Lesions Associated with HIV serostatus, CD4 Cell Counts, and human papillomavirus test results. JAMA2005; 293(12): 1471–1476. [PubMed] [Google Scholar]

34. Harro CD, Pang Y-YS, Roden RBS, Hildesheim A, Wang Z, Reynolds MJ, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 2001; 93: 284–292. [PubMed] [Google Scholar]

35. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovagin*l papillomavirus infection in young women. N. Engl. J. Med. 1998; 338: 413–428. [PubMed] [Google Scholar]

36. Holcomb K, Abulafia O, Matthews RP, Chapman JE, Borges A, Lee YC, et al. The significance of ASCUS cytology in HIV-positive women. Gynecol Oncol. 1999; 75(1): 118–21. [PubMed] [Google Scholar]

37. Huh WK, Ault KA, Chelmow D. Use of Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening: Interim Clinical Guidance. J Lower Gen Tract Dis2015;19: 91–96 [PubMed] [Google Scholar]

38. Jin XW, Cash J, Kennedy AW. Human papillomavirus typing and the reduction of cervical cancer risk. Cleveland Clin. J. Med. 1999; 66: 533–539. [PubMed] [Google Scholar]

39. Juneja A, Sehgal A, Mitra AB, Pandey A. A survey on risk factors associated with cervical cancer. Indian J Cancer. 2003; 40(1): 15–22. [PubMed] [Google Scholar]

40. Kim HJ, Kim H-J. Current status and future prospects for human papillomavirus vaccines. Arch. Pharm. Res. 2017:1–14. [PubMed] [Google Scholar]

41. Kivistic A, Lang K, Baili P, Anttila A, Veerus P. Women's knowledge about cervical cancer risk factors, screening, and reasons for non-participation in cervical cancer screening programme in Estonia. BMC Women's Health. 2011; 11: 43. [PMC free article] [PubMed] [Google Scholar]

42. Leinonen MK, Nieminen P, Lönnberg S, Malila N, Hakama M, Pokhrel A, et al. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirua DNA testing: prospective randomised trial in Finland. BMJ. 2012; 345; e7789. [PMC free article] [PubMed] [Google Scholar]

43. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int. J. Cancer2011; 128: 927–935. [PubMed] [Google Scholar]

44. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol2013; 121: 829–46. [PubMed] [Google Scholar]

45. Moscicki AB, Palefsky J, Smith G, Siboshski S, Schoolnik G. Variability of human papillomavirus DNA testing in a longitudinal cohort of young women. Obstst. Gynecol. 1993; 82: 578–585. [PubMed] [Google Scholar]

46. Munagala R, Kausar H, Munjal C, Gupta RC. Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells. Carcinogenesis2011; 32: 1697–1705. [PubMed] [Google Scholar]

47. Okunade KS, Nwogu CM, Oluwole AA, Anorlu RI. Prevalence and risk factors for genital high-risk human papillomavirus infection among women attending the out-patient clinics of a university teaching hospital in Lagos, Nigeria. The Pan African Medical Journal. 2017; 28: 227. [PMC free article] [PubMed] [Google Scholar]

48. Okunade KS, Sunmonu O, Osanyin GE, Oluwole AA. Knowledge and Acceptability of Human Papillomavirus Vaccination among Women Attending the Gynaecological Outpatient Clinics of a University Teaching Hospital in Lagos, Nigeria. J Trop Med. 2017; 2017: 8586459. [PMC free article] [PubMed] [Google Scholar]

49. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int. J. Gynecol. Pathol. 1993; 12: 186–192. [PubMed] [Google Scholar]

50. Perlman S, Wamai RG, Bain PA, Welty T, Welty E, Ogembo JG. Knowledge and awareness of HPV vaccine and acceptability to vaccinate in sub-Saharan Africa: A systematic review. PLoS ONE. 2014; 9(3): e90912. [PMC free article] [PubMed] [Google Scholar]

51. Philips DH, NiShé MSmoking-related DNA adducts in human cervical biopsies. IARC Sci. Publ. 1993; 124: 327–330. [PubMed] [Google Scholar]

52. Qiao YL, Sellors JW, Eder PS, Bao YP, Lim JM, Zhao FHet al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol. 2008; 9(10): 929–936. [PubMed] [Google Scholar]

53. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up four European randomised controlled trials. The Lancet2013; 383(9916): 524–532. [PubMed] [Google Scholar]

55. Sapp M, Volpers C, Muller M, Streck RE. Organization of the major and minor capsid proteins in human papillomavirus type 33 virus-like particles. J. Gen. Virol. 1995; 76: 2407–2412. [PubMed] [Google Scholar]

56. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. Am J Clin Pathol2012; 137: 516–42. [PubMed] [Google Scholar]

57. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet2007; 370: 890–907. [PubMed] [Google Scholar]

58. Schiffman M, Wentzensen N. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol. Biomarkers Prev. 2013; 22: 553–560. [PMC free article] [PubMed] [Google Scholar]

59. Shields TS, Brinton LA, Burk RD, Wang SS, Weinstein SJ, Ziegler RGet al. A case-control study of risk factors for invasive cervical cancer among US women exposed to oncogenic types of human papillomavirus. Cancer Epidemiol Biomarkers Prev. 2004; 13(10): 1574–1582. [PubMed] [Google Scholar]

60. Singh DK, Anastos K, Hoover DR, Burk RD, Shi Q, Ngendahayo L, et al. Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis2009; 199(12): 1851–1861. [PMC free article] [PubMed] [Google Scholar]

61. Stanley MA, Pett MR, Coleman N. HPV: from infection to cancer. Biochemical Society Transactions. 2007; 35(6): 1456–1460. [PubMed] [Google Scholar]

62. Syrjänen KJNatural history of genital human papillomavirus infections In Lacey C (ed.), Papillomavirus reviews. Leeds University Press, Leeds, United Kingdom: 1996: p.189–206. [Google Scholar]

63. Torrisi A, Del Mistro A, Onnis GL, Merlin F, Bertorelle R, Minucci D. Colposcopy, cytology and HPV testing in HIV-positive and HIV-negative women. Eur. J. Gynecol. Oncol. 2000; 21: 168–172. [PubMed] [Google Scholar]

64. Unger ER, Eliav B. Human Papillomavirus and Cervical CancerEmerg Infect Dis. 2004; 10(11): 2031–2032. [PMC free article] [PubMed] [Google Scholar]

65. Vici PTargeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. Expert Rev. Vaccin. 2016; 15(10): 1327–1336. [PMC free article] [PubMed] [Google Scholar]

66. Villa LL. Human papillomaviruses and cervical cancer. Adv. Cancer Res. 1996; 71:321–341. [PubMed] [Google Scholar]

67. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol1999; 189: 12–19. [PubMed] [Google Scholar]

68. WHO, “World Health Organization Human papillomavirus vaccines WHO position paper,” The Weekly Epidemiological Record. 2009; 15(84): 117–132. [Google Scholar]

69. WHO – World Health Organization. HPV vaccination In: Comprehensive Cervical Cancer Control - A guide to essential practice.2nd ed. World Health Organization 2014. Geneva, Switzerland: WHO Press; p110–128. [PubMed] [Google Scholar]

70. Williams VM, Filippova M, Soto U, Duerksen-Hughes PJ. HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress. Fut Virol. 2011; 6: 45–57. [PMC free article] [PubMed] [Google Scholar]

71. Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015; 136(2): 189–97. [PubMed] [Google Scholar]

73. Yang X, Jin G, Nakao Y, Rahimtula M, Pater MM, Pater A. Malignant transformation of HPV-16 immortalized human endocervical cells by cigarette smoke condensate and characterization of multistage carcinogenesis. Int J. Cancer1996; 65: 338–344. [PubMed] [Google Scholar]

74. Zhang J-J, Cao X-C, Zheng X-Y, Wang H-Y, and Li Y-W. Feasibility study of a human papillomavirus E6 and E7 oncoprotein test for the diagnosis of cervical precancer and cancer. J Int Med Res. 2018; 46(3): 1033–1042. [PMC free article] [PubMed] [Google Scholar]